Cargando…
Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism
No therapy exists for non-alcoholic fatty liver disease (NAFLD). However, glucagon-like peptide receptor agonists (GLP-1RAs) showed a beneficial effect on NAFLD, although the underpinning mechanisms remain unclear due to their pleiotropic effects. We examined the implicated signaling pathways using...
Autores principales: | Errafii, Khaoula, Khalifa, Olfa, Al-Akl, Neyla S., Arredouani, Abdelilah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138370/ https://www.ncbi.nlm.nih.gov/pubmed/35625757 http://dx.doi.org/10.3390/biomedicines10051020 |
Ejemplares similares
-
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
por: Errafii, Khaoula, et al.
Publicado: (2021) -
Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells
por: Khalifa, Olfa, et al.
Publicado: (2023) -
Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
por: Khalifa, Olfa, et al.
Publicado: (2022) -
Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy
por: Khalifa, Olfa, et al.
Publicado: (2022) -
Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern population-based cross-sectional study
por: Al Akl, Neyla S., et al.
Publicado: (2021)